VAF347
Based on 3 publication(s) in Google Scholar
VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14+CD11b+ monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory effects.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 574759-62-9
- Formula: C17H11ClF3N3
- Molecular Weight:349.74
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) VAF347
More
Biological Activity
Aryl hydrocarbon receptor[1]
VAF347 (0.01-20 μM; 48-72 hours; HL-60 cells) treatment enhances retinoic acid-induced cell cycle arrest[1].
?
VAF347 (20 μM; 48 hours; HL-60 cells) treatment augments retinoic acid-induced expression of AhR, Lyn, Vav1, and c-Cbl as well as p47phox. Several interactions of partners in the signalsome appear to be enhanced: Fgr interaction with c-Cbl, CD38, and with pS259c-Raf and AhR interaction with c-Cbl and Lyn[1].
?
VAF347 inhibits IL-4+ GM-CSF induced IL-6 production in MM1 cells with an IC50 of ~5 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60 cells
-
Concentration:10 nM, 100 nM, 1 μM, 10 μM, 20 μM
-
Incubation Time:48 hours or 72 hours
-
Result:Enhanced retinoic acid-induced cell cycle arrest in G1/0.
-
Cell Line:HL-60 cells
-
Concentration:20 μM
-
Incubation Time:48 hours
-
Result:Augmented retinoic acid-induced expression of AhR, Lyn, Vav1, and c-Cbl as well as p47phox.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 574759-62-9
-
Appearance Solid
-
Molecular Weight 349.74
-
Formula C17H11ClF3N3
-
Color White to off-white
-
SMILES
FC(C1=CC=C(NC2=NC=CC(C3=CC=CC(Cl)=C3)=N2)C=C1)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Chem Biol
Identification of aryl hydrocarbon receptor as a functional target that enhances astrocytic ApoE secretion. [Abstract]2026 Jan 15;33(1):91-101.e12. PMID: 41483807 -
J Nutr Biochem
Genistein upregulates AHR to protect against environmental toxin-induced NASH by inhibiting NLRP3 inflammasome activation and reconstructing antioxidant defense mechanisms. [Abstract]2023 Nov:121:109436. PMID: 37666477 -
Cytotherapy
Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer. [Abstract]2024 Feb;26(2):136-144. PMID: 38149947
Solvent & Solubility
DMSO : 31.25 mg/mL (89.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (5.95 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ibabao CN, et al. The AhR agonist VAF347 augments retinoic acid-induced differentiation in leukemia cells. FEBS Open Bio. 2015 Apr 8;5:308-18. [Content Brief]
[2]. B Paige Lawrence, et al. Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood. 2008 Aug 15;112(4):1158-65. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8593 mL | 14.2963 mL | 28.5927 mL | 71.4817 mL |
| 5 mM | 0.5719 mL | 2.8593 mL | 5.7185 mL | 14.2963 mL | |
| 10 mM | 0.2859 mL | 1.4296 mL | 2.8593 mL | 7.1482 mL | |
| 15 mM | 0.1906 mL | 0.9531 mL | 1.9062 mL | 4.7654 mL | |
| 20 mM | 0.1430 mL | 0.7148 mL | 1.4296 mL | 3.5741 mL | |
| 25 mM | 0.1144 mL | 0.5719 mL | 1.1437 mL | 2.8593 mL | |
| 30 mM | 0.0953 mL | 0.4765 mL | 0.9531 mL | 2.3827 mL | |
| 40 mM | 0.0715 mL | 0.3574 mL | 0.7148 mL | 1.7870 mL | |
| 50 mM | 0.0572 mL | 0.2859 mL | 0.5719 mL | 1.4296 mL | |
| 60 mM | 0.0477 mL | 0.2383 mL | 0.4765 mL | 1.1914 mL | |
| 80 mM | 0.0357 mL | 0.1787 mL | 0.3574 mL | 0.8935 mL |